Int J Clin Oncol: 4-day MEA treatment for velvet cancer and high-risk GTN

The purpose of this study was to assess the efficacy and toxicity of 4 days of chemotherapy and methotrexate, optoside and linemycin D (MEA) fordiagnosispatients with velvet cancer and high-risk pregnancy nourishing cytoma (GTN)between January 1999 and December 2015, 29 patients received four days of MEA treatment after being diagnosed with velvet cancer or high-risk GTNA retrospective evaluation of 4 days of meA's complete remission and adverse reactions was carried outresults, the total remission rates were 79.3% (23/29) and 87.5% (21/24) for all patients and patients receiving 4 days of MEA as first-line treatment, respectivelyOf the six patients who developed resistance to 4-day MEA, 3 developed complete remission through other treatments and 3 died of illnessThe main adverse reactions are white blood cell reduction, anemia and nauseaOf the 23 patients cured with 4 days of MEA, 14 were treated with efonucleoside and linemycin D (EA) regimens due to leukocyte reduction, hepatotoxicity and stomatitisOf the 20 patients who required hormone therapy, 15 had a normal menstrual cycle after treatment5 patients conceived a total of 9 times (7 cases of live births, 2 cases of spontaneous abortion)There are no premature or low birth weight babies, and there are no congenital malformationsin general, the results show that 4 days of MEA treatment for velvet cancer and high-risk GTN efficacy and adverse reactions may be at the same level as EMA/COHowever, further study is needed to determine how to change the four-day MEA treatment regime to the criteria for the EA programme